Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: A real-world experience from Belgium

Introduction: Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods: Eighty-seven GT4 treatment-naïve or -Interfe... Mehr ...

Verfasser: Degré, D. (Delphine)
Sersté, T. (Thomas)
Lasser, L. (Luc)
Delwaide, J. (Jean)
Starkel, P. (Peter)
Laleman, W. (Wim)
Langlet, P. (Philippe)
Reynaert, H. (Hendrik)
Bourgeois, S. (Stefan)
Vanwolleghem, T. (Thomas)
Dastis, S.N. (Sergio Negrin)
Gustot, T. (Thierry)
Geerts, A. (Anja)
Van Steenkiste, C. (Christophe)
Galocsy, C. (C.) de
Lepida, A. (Antonia)
Orlent, H. (Hans)
Moreno, C. (Christophe)
Dokumenttyp: Artikel
Erscheinungsdatum: 2017
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27382908
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://repub.eur.nl/pub/95850